The U.S. Food and Drug Administration (FDA) has approved semaglutide, a type 2 diabetes drug that recently gained social media fame, for weight loss for teenagers with obesity.
The drug, approved under the brand name Wegovy, is so far the only prescription anti-obesity medicine for children as young as 12 with once-a-week injection, according to Novo Nordisk, the company that produces Wegovy. It is also sold under other names such as Ozempic and Rybelsus.
